ISRCTN16192422已完成不适用
Temozolomide in children with recurrent or refractory central nervous system (CNS) tumours [Temozolomide bij kinderen met een gerecidiveerde of refractaire centraal zenuwstelsel tumor]
Dutch Childhood Oncology Group (Stichting Kinder Oncologie [SKION]) (The Netherlands)0 个研究点目标入组 54 人开始时间: 2005年12月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged 3 - 18 years
- •2. Pathology: primitive neuroectodermal tumour (PNET)/high grade glioma
- •3. Measurable tumour
- •4. Lansky score greater than 50%
- •5. Expected life span of 12 weeks or more
- •6. Informed consent
排除标准
- •Non-conformation to inclusion criteria
研究者
相似试验
招募中
不适用
Temozolomide in children with recurrent or refractory CNS tumors.recurrent primitive neuro ectodermal tumors and recurrent high grade gliomas of the CNS in children.NL-OMON28755SKION (Stichting Kinder Oncologie); Schering Plough54
已完成
2 期
Multicombination Therapy of Temozolomide, Vincristine, and Interferon-beta with Radiotherapy for Malignant GliomaJPRN-UMIN000040599Department of Neurosurgery, Hirosaki University School of Medicine50
已完成
不适用
Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)-C189 Colon, unspecified-C349 Bronchus or lung, unspecified-C760 Head, face and neck-C159 Oesophagus, unspecifiedOesophagus, unspecifiedColon, unspecifiedBronchus or lung, unspecifiedHead, face and neckC159C189C349C760PER-023-07SCHERING PLOUGH RESEARCH INSTITUTE,
已完成
不适用
Phase II study of Temozolomide monotheraphy in patients with first line treatment-refractory neuroendocrine carcinomaeuroendocrine carcinoma (Grade3)JPRN-UMIN000010549Yokohama City University Hospital13
尚未招募
2 期
se of romiplostim in children with cancers requiring high dose of chemotherapy, to accelerate platelet count recoveryCTRI/2023/02/049906Dr. SHIVAM BANSA